Individualised Care Vs. the Polypill Debate
For years, there’s been a growing conversation about whether everyone over a certain age should take preventive medication. The so-called ‘polypill’ approach proposes that all adults over 50 be prescribed a combination of low-dose statins, blood pressure medication, and other cardiovascular drugs as a one-size-fits-all strategy to prevent heart attacks and strokes.
While it sounds like a simple solution – linked with fewer heart attacks, deaths, and hospitalisations – medicine isn’t just about statistics, it’s about people. When it comes to long-term prevention, personalised, data-driven care is far more effective than blanket prescriptions.
The appeal of the polypill
The concept of the polypill, or fixed-dose combination (FDC) therapy, was born from good intentions. Cardiovascular disease remains the leading cause of death worldwide, and studies have shown that statins and blood pressure medications can significantly reduce risk when used appropriately. Combining these medications into a single daily pill could make prevention easier, more affordable, and more consistent.
One review found that polypills were associated with an 11 per cent lower risk of death from any cause and a 29 per cent lower risk of atherosclerosis cardiovascular disease events compared with people who did not take them.
However, as with many broad public health strategies, simplicity can come at a cost. While the polypill may reduce overall population risk, it overlooks the individual variation that determines who truly benefits, and who might not.
Why one size doesn’t fit all
Cardiovascular health is complex. It’s influenced not just by cholesterol and blood pressure, but also by inflammation, hormonal balance, metabolic function, genetics, and even environmental exposures. Two people of the same age can have completely different cardiovascular risk profiles. One may have mild hypertension and poor metabolic control, while the other has optimal blood sugar levels, strong vascular health, and no evidence of inflammation.
Prescribing the same medication to someone simply because they’ve passed a certain birthday fails to recognise this complexity. It risks over-treating some patients, introducing unnecessary side effects (one article mentions concerns about dizziness or falls from low blood pressure), and under-investigating others, whose root causes may lie outside traditional risk factors.
An individualised, functional medicine approach
Dr Grosser’s philosophy is simple – prevent disease by understanding the biological mechanisms behind it.
Instead of automatically prescribing medication, he begins with a comprehensive assessment that includes metabolic and hormonal testing, inflammation markers and advanced lipid profiling. TruAge biological age testing can inform how quickly a patient’s cardiovascular system is aging on a cellular level.
This approach often reveals hidden contributors to cardiovascular risk, such as insulin resistance, thyroid dysfunction, chronic stress, or nutrient deficiencies, that wouldn’t appear on a standard cholesterol test. Addressing these root causes early can significantly reduce disease risk without resorting to lifelong medication for every patient.
Choose a tailored treatment plan
If you’re approaching midlife and want to understand your true cardiovascular risk, Dr Grosser’s integrative assessment can provide a clear, individualised roadmap. Through advanced functional testing and personalised treatment planning, you’ll gain the insight to make informed choices about prevention, without unnecessary medication.
To find out more, book a consultation with Dr Konrad Grosser today.
